DARIOHEALTH DL-,0001

DarioHealth reported an adjusted loss of $0.85 per share in Q2 2026, beating consensus estimates, while revenue of $5.18 million missed analyst expectations. The company improved gross margins to 62%, cut operating expenses and reduced net loss to $7.9 million. Management emphasized a strategic shift toward higher‑margin, recurring contracts and expects accelerated revenue growth in the second half of 2026, supported by around $13.1 million in late‑stage ARR. The stock rose modestly after the release but remains significantly down year‑to‑date. » More on de.investing.com

DarioHealth reports a sequential revenue rise of 7.7% to $5.6 million in Q1 2026 and a GAAP gross margin of 57% (prior quarter 54%). Operating expenses fell 21% to $10.5 million, and the operating GAAP loss improved 22% to $7.3 million. The shares rose 2.19% in premarket trading. The company is shifting revenue toward recurring consumer revenues, relying on the AI engine DarioIQ to boost member retention, and is targeting cash-flow breakeven and further revenue growth. » More on de.investing.com

DarioHealth signed 85 new agreements in 2025, generating $12.9 million of contracted and late-stage ARR and expanding its commercial pipeline to $122 million. Annual revenue fell to $22.4 million due to a single legacy client non-renewal, but Q4 revenue rose sequentially to $5.2 million as new contracts begin to ramp. The company reduced operating expenses by ~31% in 2025, achieved higher gross margins, ended the year with $26.0 million in cash, and expects to narrow non-GAAP operating loss by ~30% in 2026. Management targets cash-flow breakeven by mid-2027 and highlights multi-condition platform deployments and large payer/channel partnerships as key growth drivers. » More on finance.yahoo.com